Latest Artificial Intelligence News

Spark New Zealand has launched its ambitious SPK-30 strategy, refocusing on core connectivity services with heavy investment in 5G and AI-driven customer experiences. The plan aims to deliver stable returns and sustainable growth amid evolving market dynamics.

Carnegie Clean Energy has successfully raised $2.116 million through a Share Purchase Plan, fueling key wave energy projects and global business development efforts.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Pathkey.AI’s TrialKey platform has demonstrated a 73% alignment with actual biotech trial outcomes, showing an average hypothetical share price gain of 76%, underscoring AI’s growing role in clinical trial prediction and biotech investing.

Argent Minerals updates investors on its flagship Kempfield Project, highlighting resource expansion, exploration upside, and development plans aimed at early production and cash flow generation.

Savana Asset Management signals a strategic shift favoring US small caps amid easing Federal Reserve rates and cooling enthusiasm for mega-cap tech stocks. Kohl’s standout earnings further boost the fund’s outlook.

Carnegie Clean Energy is closing its Share Purchase Plan on 8 September, offering shareholders a discounted entry to fund key ocean energy projects. The capital raise aims to accelerate development in Europe, the US, and Australia.

InFocus Group Holdings launches a new division focused on digital assets, AI, and big data, supported by a conditional $10 million financing from Mythos Group. The move aims to accelerate innovation in gamification and blockchain ventures.

Cycliq Group Limited reported a 3.8% revenue increase to AUD 4.78 million for FY2025 alongside a significant reduction in net loss, driven by strategic product enhancements and a new AI partnership. The company also strengthened its board and launched a revamped e-commerce platform, positioning itself for growth despite ongoing legal and operational risks.

Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.